Pfizer-BioNTech wins FDA approval for XFG-adapted 2026-2027 COVID vaccine in high-risk groups

Reuters2026/08/27 20:32

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

FDA cleared Pfizer’s updated Comirnaty XFG COVID-19 shot for adults 65+.
Authorization also covers ages 5-64 with at least one high-risk underlying condition.
BioNTech partnered on the vaccine; US shipments start immediately ahead of the 2026-2027 season.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608271630BIZWIRE_USPR_____20260818_BW295148) on August 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Pfizer-BioNTech wins FDA approval for XFG-adapted 2026-2027 COVID vaccine in high-risk groups

You may also like

Crypto prices